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Plasmid-mediated 
carbapenem and colistin 
resistance in a clinical 
isolate of Escherichia coli
Acquired resistance to polymyxins 
is increasingly reported in Entero-
bacteriaceae, and particularly in 
Klebsiella pneumoniae. This increased 
resistance is extremely worrying 
considering that polymyxins are 
last-resort antibiotics for treating 
infections due to carbapenem-
resistant Enterobacteriaceae.
Findings from a study by Yi-Yun Liu 
and colleagues1 identiﬁ ed the plasmid-
mediated mcr-1  gene encoding a 
phosphoethanolamine transferase 
conferring resistance to polymyxins. 
This transmissible gene was identiﬁ ed 
from Escherichia coli and K pneumoniae 
isolates from animal sources (farm 
pigs, and retail meat from pork 
and chicken), but also from human 
sources, from several Chinese regions.1 
We report here an E coli strain 
harbouring both plasmid-borne 
carbapenem and colistin resistance 
genes. That strain was recovered from 
urine cultures of an 83-year-old man 
who was admitted to hospital for 
diverticulitis in December, 2015, in 
Switzerland. He had renal deﬁ ciency 
and was therefore submitted to 
regular dialysis. E coli isolate KRI 
was resistant to most β-lactams 
(remaining susceptible to aztreonam) 
and resistant or of intermediate 
suscepti bility to carbapenems (mini-
mum inhibitory concentrations 
were 4 μg/mL for imipenem, 
4 μg/mL for ertapenem, and 2 μg/
mL for meropenem).2 This isolate was 
also resistant to chloramphenicol, 
gentamicin, kanamycin, tobramycin, 
sulfonamides, tetracycline, co-
trimoxazole, and fluoroquinolones, 
remaining susceptible only to 
amikacin, tigecycline, and fosfomycin. 
Noteworthy, it was resistant to 
colistin, with a minimum inhibitory 
concentration of 4 μg/mL. 
PCR and sequencing revealed 
that E coli KRI harboured the blaVIM-1 
carbapenemase4 gene and the mcr-1 
gene. Additionally, the floR gene 
encoding resistance to florfenicol 
was identified. Mating-out assays 
done as previously described3 
identiﬁ ed the mcr-1 gene on a roughly 
60 kb plasmid, encoding resistance to 
colistin, chloramphenicol, ﬂ orfenicol, 
and co-trimoxazole.  Multilocus 
sequence typing identiﬁ ed E coli KRI as 
belonging to clonal complex (CC) 23.4
The origin of this E coli strain remains 
unknown since the patient did not travel 
abroad. An animal origin of the strains is 
indicated on the basis of the large usage 
of colistin in veterinary medicine that 
may have selected for colistin resistance, 
the florfenicol resistance trait widely 
observed with animal isolates related to 
ﬂ orfenicol usage in veterinary medicine, 
and the recurrent identiﬁ cation of VIM-
1-producing E coli strains in veterinary 
medicine . An animal origin of this 
strain reinforces the idea that antibiotic 
resistance issues should be considered 
as a one-health one-world approach. 
Finally, such accumulation of multidrug 
resistance traits may correspond to an 
ultimate step toward pandrug resistance 
in Enterobacteriaceae, considering 
that no new drugs against polymyxin 
resistant and metallo-β-lactamase 
producers will be marketed in the near 
future.
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